Comparison of Lanreotide and Octreotide LAR use and outcomes for gastrointestinal neuroendocrine tumors in British Columbia, Canada

#3453

Introduction: The long-acting somatostatin analogues (LA-SSAs) octreotide LAR (OCT) and lanreotide (LAN) improve progression-free survival in neuroendocrine tumors (NETs), however no head-to-head comparison exists. We compared treatment patterns and efficacy in a population-based cohort from British Columbia, Canada.

Aim(s): To compare the use and associated outcomes of lanreotide and octreotide LAR in British Columbia, Canada.

Materials and methods: The long-acting somatostatin analogues (LA-SSAs) octreotide LAR (OCT) and lanreotide (LAN) improve progression-free survival in neuroendocrine tumors (NETs), however no head-to-head comparison exists. We compared treatment patterns and efficacy in a population-based cohort from British Columbia, Canada.

Conference:

Presenting Author: Paul A

Authors: Paul A, Mendis S, Jao J, Boutin M, Safro M,

Keywords: lanreotide, octreotide LAR, neuroendocrine tumor, overall survival,